+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Younger adults with acute myeloid leukemia in remission for ≥ 3 years have a high likelihood of cure: The ECOG experience in over 1200 patients



Younger adults with acute myeloid leukemia in remission for ≥ 3 years have a high likelihood of cure: The ECOG experience in over 1200 patients



Leukemia Research 38(8): 901-906



We examined 1229 younger patients with acute myeloid leukemia who achieved CR1 on Eastern Cooperative Oncology Group trials. We defined late relapse as occurring after ≥ 3 years of CR1. With median follow-up of 11.3 years, there were 14 late relapses (1.1% of CR1 patients; 3.3% of 3-year CR1 patients). Eight achieved second CR and median overall survival after late relapse was 3.2 years. Most patients tested (9/11) had a normal karyotype at diagnosis; none had new cytogenetic abnormalities at relapse. Late relapse is rare and nearly all 3-year CR1 patients are cured. If late relapse occurs, outcomes are relatively favorable.

(PDF emailed within 0-6 h: $19.90)

Accession: 056974493

Download citation: RISBibTeXText

PMID: 24986381

DOI: 10.1016/j.leukres.2014.05.018


Related references

The role of allogeneic bone marrow transplantation in the younger adults with acute myeloid leukemia in first remission A ten-year experience of the BGMT group. Blood 88(10 SUPPL 1 PART 1-2): 683A, 1996

Recombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: results from Cancer and Leukemia Group B 19808. Cancer 120(7): 1010-1017, 2014

Escalating the intensity of post-remission therapy improves the outcome in acute myeloid leukemia: the ECOG experience. The Eastern Cooperative Oncology Group. Leukemia 6 Suppl 2: 116-119, 1992

Post-remission therapy in adults with acute myelogenous leukemia: the Eastern Cooperative Oncology Group (ECOG) experience. Leukemia 6 Suppl 4: 75-77, 1992

Long-term follow-up of Asian patients younger than 46 years with acute myeloid leukemia in first complete remission: comparison of allogeneic vs. autologous hematopoietic stem cell transplantation. Leukemia and Lymphoma 48(1): 72-79, 2007

Randomized Phase II Study of Clofarabine-Based Consolidation for Younger Adults With Acute Myeloid Leukemia in First Remission. Journal of Clinical Oncology 35(11): 1223-1230, 2017

Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia in first complete remission An intention-to-treat analysis of the EORTC/GIMEMA AML-10 trial. Blood 102(4): 1232-1240, August 15, 2003

Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial. Blood 102(4): 1232-1240, 2003

Treatment of acute myeloid leukemia younger adults: the GOELAM experience. Annals of Hematology 83 Suppl 1: S104-S105, 2004

High Remission Rate with the FLAG-IDA Regimen in Myelodysplastic Syndromes and Secondary Acute Myeloid Leukemia Patients up to 70 Years Old. Blood 100(11): Abstract No 4900, November 16, 2002

High-dose cytarabine and idarubicin induction produces a high complete remission rate in previously untreated de novo acute myeloid leukemia patients gtoreq 60 years old. Blood 96(11 Part 1): 322a, November 16, 2000

Feasability of High Dose Melphalan and Peripheral Blood Stem Cell Support for Patients over 60 Years with Acute Myeloid Leukemia in First Remission. Blood 100(11): Abstract No 3397, November 16, 2002

Potential cure of acute myeloid leukemia : analysis of 1069 consecutive patients in first complete remission. Cancer 110(12): 2756-2760, 2007

Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia. Blood 109(7): 2744-2750, 2006

High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial. Journal of Clinical Oncology 32(3): 219-228, 2014